Gilead Sciences Inc. said Tuesday it has appointed Andrew Dickinson as chief financial officer, effective Nov. 1. Dickinson is currently executive vice president corporate development and strategy and will become a member of the senior leadership team reporting to Chief Executive Daniel O’Day. The executive joined the company in 2016 after stints at Lazard and Myogen Inc., which Gilead acquired in 20016. Shares were not yet active premarket, but have gained 3% in 2019, while the S&P 500 has gained 18%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
This article does not constitute investment advice. We are not affiliated or responsible for content hosted on 3rd-party sites in any way.